Edit

EMBL Ventures

https://www.embl-ventures.com

Last activity: 19.10.2024

Active

EMBL Ventures invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment.

News

Mentions

Employees: 1-10

News 72

Date	Title	Description
15.10.2024	Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial	-
07.05.2024	Topas Therapeutics Appoints Hugo Fry as CEO	-
27.02.2024	Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP	-
30.01.2024	Allecra Licensor Advanz receives positive CHMP opinion for EXBLIFEP	-
27.06.2023	Allecra Therapeutics Submits New Drug Application to the U.S. FDA	-
05.10.2022	Allecra Publishes Final Phase 3 ALLIUM Data in JAMA	-
15.02.2022	Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer	-
13.01.2022	Allecra Therapeutics and Advanz Pharma Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe	-
12.01.2022	BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies	-
27.07.2021	Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round	-
27.07.2021	Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million)	-
23.10.2020	Allecra Therapeutics Announces Late-breaker Presentation of Phase 3 ALLIUM Trial	-
23.10.2020	Allecra Therapeutics Announces Late-breaker Presentation of Phase 3 ALLIUM Trial with Cefepime-Enmetazobactam in cUTIs at IDWeek 2020	-
19.10.2020	Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing	-
19.10.2020	Topas Therapeutics Appoints Klaus Martin, Ph.D. as Chief Executive Officer	-
02.07.2020	Immatics Announces Completion of Business Combinationand Listing on NASDAQ	-
04.06.2020	Immatics Appoints Cedrik Britten as Chief Medical Officer	-
17.03.2020	Immatics Announces Business Combination with Arya Sciences	-
25.02.2020	Allecra Therapeutics Announces Positive Top-Line Results for Phase 3	-
21.02.2020	Immatics and GSK Partner to Develop Novel Adoptive Cell Therapies	-
18.12.2019	Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris	-
24.09.2019	Amphivena Closes $62 Million Series C Financing	-
12.09.2019	Crescendo Biologics to collaborate with world-leading oncology groups at the University of Oxford and the University of Surrey	-
28.08.2019	Immatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies	-
19.07.2019	Immatics Presents First Cohort Data on the ACTolog® Personalized Multi-Target Cell Therapy Trial Demonstrating Safety and T-cell Persistence in Treated Cancer Patients	-
08.07.2019	Immatics Appoints Harpreet Singh as Chief Executive Officer	-
09.04.2019	Immatics Initiates Third Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers	-
26.02.2019	Immatics announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers	-
03.01.2019	US Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies	-
20.12.2018	Nature publication reports first-in-human trial for a personalized cancer immunotherapy	-
27.11.2018	Arsanis and X4 Pharmaceuticals Agree to Merger	-
25.10.2018	Opsona Therapeutics to present results on Tomaralimab study at the 60th Annual Meeting of the American Society of Hematology (ASH)	-
13.09.2018	EMBL Ventures Portfolio Company, ViraTherapeutics Acquired by Boehringer Ingelheim in EUR 210 Million (USD 245 Million) Transaction.	-
11.09.2018	Crescendo Biologics Appoints Dr Pavel Pisa as Chief Medical Officer	-
23.08.2018	Allecra Therapeutics Successfully Enters Next Development Phase	-
12.07.2018	Immatics Enters into a Strategic Partnership with Genmab	-
14.05.2018	Immatics Appoints Stephen Eck as Chief Medical Officer US	-
30.04.2018	Crescendo Biologics Ltd. Raises $70 Million (€57 Million) in Series B Financing	-
24.04.2018	Topas Therapeutics and BI Sign Multi-Year Collaboration and Option Agreement	-
26.03.2018	Allecra Therapeutics Announces Positive Top-Line Results from Phase 2	-
12.03.2018	ViraTherapeutics starts 2nd development program with Boehringer Ingelheim	-
15.02.2018	Allecra Therapeutics Announces Fast Track Designation for Lead Antibiotic	-
25.01.2018	Topas Therapeutics serves as exclusive translational partner for CRC	-
21.12.2017	Immatics Proprietary Target Selected for the Devel. of Cancer Immunotherapies	-
19.12.2017	Immatics Appoints Thomas Ulmer as CFO	-
19.12.2017	Apellis Pharmaceuticals Appoints Timothy Sullivan as CFO	-
08.12.2017	Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2	-
04.12.2017	Allecra Therapeutics Announces New Staged Financing Deal	-
30.11.2017	Crescendo Biologics Wins “Licensing Deal of the Year” at the Scrip Awards 2017	-
20.11.2017	Arsanis Announces Closing of Initial Public Offering	-
13.11.2017	Apellis Pharmaceuticals Announces Closing of its Initial Public Offering	-
02.11.2017	Topas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund	-
26.10.2017	Topas Therapeutics Appoints Rupert Sandbrink as CDO and CMO	-
04.10.2017	Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies	-
28.09.2017	Immatics Initiates the First Phase I Clinical Trial of its Unique ACTengine®	-
07.09.2017	Allecra Announces Initiation of a Phase 2 Clinical Trial	-
22.08.2017	Immatics Initiates a Phase I trial using ACTolog	-
16.06.2017	Crescendo Biologics Wins “Emerging Star of the Year” Award at the European Mediscience Awards	-
08.05.2017	EMBL Ventures portfolio company Luxendo acquired by Bruker	-
26.04.2017	Arsanis Completes $45.5 Million Series D Financing	-
04.04.2017	Paul Sekhri joins Topas Therapeutics as Chairman of the Board	-
04.04.2017	Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer	-
27.02.2017	Arsanis and Adimab Enter Into License Agreement	-
24.01.2017	Arsanis Announces First Patient Dosed in Global Phase 2 Study	-
10.01.2017	Crescendo partners with Genedata	-
09.01.2017	Luxendo announces Series A extension	-
20.12.2016	Opsona announces preliminary MDS results	-
25.10.2016	Opsona receives orphan designation	-
10.10.2016	Crescendo enters a collaboration with Takeda	-
28.09.2016	ViraT enters collaboration with Boehringer Ingelheim	-
27.09.2016	Crescendo strengthens IP portfolio	-
22.03.2016	Topas Series A Financing	-

Mentions in press and media 1

Date	Title	Description
14.10.2015	Luxendo Closes €6M Series A Financing	Luxendo, a startup launched by the European Molecular Biology Laboratory (EMBL) and its technology transfer arm EMBLEM Technology Transfer (EMBLEM) in Heidelberg, Germany, closed a €6M Series A financing. The round was co-led by EMBL Ventur...

EMBL Ventures

News 72

Mentions in press and media 1

Reviews 0